BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare Oncology Disease Analysis: HR+/HER2- Breast Cancer

May 14, 2020

Hormone receptor-positive (HR+) is the most common breast cancer subtype, with approximately 70% of breast cancers presenting with overexpression of estrogen receptors, progesterone receptors, or both. Overexpression of the hormone receptors allows estrogen and progesterone to drive tumor growth and proliferation. Therefore, endocrine therapy remains the standard treatment for advanced patients with HR+/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Worldwide, breast cancer is the second most common cancer and the fifth leading cause of cancer-related deaths regardless of gender. In the US, breast cancer is the most common cancer in women and the fourth leading cause of cancer-related deaths, regardless of gender, behind lung cancer, colorectal cancer, and pancreatic cancer.

CDK4/6 inhibitors remain the standard treatment for advanced and metastatic HR+/HER2- patients. Datamonitor Healthcare expects their uptake to increase significantly over the forecast period as all three are projected to receive strategic label expansions into the adjuvant treatment setting for early-stage HR+/HER2- breast cancer patients.

This Datamonitor Healthcare report contains a Disease Analysis module.
Indications Covered: Breast Cancer
Back to the top Back to the top